Waldenstr öm Macroglobulinemia: Review of Pathogenesis and Management

Waldenstr öm macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M (IgM). Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton’s tyrosine kinase inhibitors have made the management of WM increasingly complex.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Seongseok Yun, Ariel Johnson, Onyemaechi Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz, Faiz Anwer Tags: Review Article Source Type: research